Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24835684 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1HRH3ALDH1A1 | |
| SCHEMBL24836106 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1HRH3ALDH1A1 | |
| SCHEMBL10254329 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC6A9S1PR1HRH3ALDH1A1 | |
| SCHEMBL12312777 | 0.83 | NPSR1 (0.35) | HRH3ALDH1A1SMN1; SMN2SIGMAR1CACNA1H | |
| SCHEMBL24193274 | 0.82 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1HRH3ALDH1A1 | |
| SCHEMBL24911013 | 0.82 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21128705 | 0.82 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1HRH3ALDH1A1 | |
| SCHEMBL16356926 | 0.82 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| Tetraxetan SCHEMBL5370171 | 0.81 | HSD17B10 (0.58) | HSD17B10SLC6A9S1PR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10102885 | 0.81 | ALDH1A1 (0.47) | HRH3ALDH1A1SMN1; SMN2SIGMAR1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230001027-A1 | METAL CHELATING AGENTS AND METHODS OF USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-05 | — | — | US | disclosed |
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020102348-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | DIMAGNO STEPHEN (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001027-A1 | METAL CHELATING AGENTS AND METHODS OF USING THE SAME | SLC30A5, SLC30A6, SLC30A7 | HSD17B10 4732/4885SLC6A9 645/4885S1PR1 3475/4885 |
| US-20220009883-A1 | THIOAMIDE-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF | ALB, TTR, ABCG2 | HSD17B10 3512/4885SLC6A9 743/4885S1PR1 2825/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | HSD17B10 4091/4885SLC6A9 2675/4885S1PR1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.